Ritter Pharmaceuticals, Inc. Employee Directory
Pharmaceutical ManufacturingCalifornia, United States2-10 Employees
Ritter Pharmaceuticals, Inc. operates in the pharmaceutical manufacturing sector with a focus on therapies that influence the gut microbiome to address gastrointestinal diseases. The company’s lead product, RP-G28, is being developed with the potential to become the first FDA-approved treatment for lactose intolerance. Beyond this, Ritter is examining how changes in gut microbial communities may affect gut health and could have potential for treating or preventing a range of GI conditions. Based in Los Angeles, California, Ritter positions itself within the broader pharmaceutical landscape as a developer of microbiome-based therapeutics. The company targets patients with gastrointestinal diseases who may benefit from new treatment options beyond current approaches. As a small organization, its current emphasis appears to be advancing its lead therapy and exploring broader applications of microbiome modulation.